header logo image


Page 222«..1020..221222223224..230240..»

Animal Genetics Market Forecast to 2027 – COVID-19 Impact and Global Analysis By Product, Genetic Material, and Services and Geography. -…

January 29th, 2021 2:52 am

New York, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Animal Genetics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product, Genetic Material, and Services and Geography." - https://www.reportlinker.com/p06010023/?utm_source=GNW However, the market is likely to get impacted by the limited number of skilled professionals in veterinary research and stringent government regulations for animal genetics during the forecast period.

The branch of genetics that deals with the study of gene variation and inheritance in companion, domestic and wild animals is called as animal genetics.Animal genetics are used for genetic trait testing, DNA testing, and genetic disease treatment.

Animal genetics is one of the best mainstays of livestock development (alongside animal nutrition, animal health, and husbandry concerns such as housing). According to the Food and Agriculture Organization of the United Nations, it is a wide field, ranging from characterization to maintenance to genetic improvement, and involves activities at local, national, regional, and global scales.Increasing population and rapid urbanization across the world has resulted in growing preference for animal derived food products such as dairy products and meat that contain high protein.The demand for animal derived proteins and food products, which, in turn drives the growth of animal genetics market.

Growing focus on developing superior animal breeds using genetic engineering to obtain high reproduction rates for large-scale production of modified breeds is expected to drive animal genetics market during the forecast period.Based on product, the market is segmented into poultry, porcine, bovine, canine, and others.The porcine segment held the largest share of the market in 2019, whereas the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Growth of this segment is attributed to rise in production of porcine and increase in pork consumption across the globe.Based on genetic material, the market is segmented into semen and embryo. The embryo segment held the largest share of the market in 2019, and the semen segment is anticipated to register the highest CAGR in the market during the forecast period.COVID-19 pandemic has become the most significant challenge across the world.This challenge would be frightening, especially in developing countries across the globe, as it may lead to reducing imports due to disruptions in global trade, which further increases the shortages of meat and dairy product supplies, resulting in a considerable price increase.

Asian countries such as China, South Korea, and India are severely affected due to COVID-19 outbreak.The World Health Organization, Food and Drug Administration, American Pet Products Association, American Veterinary Medical Cattle Health, and Welfare Group for Disease Control and Prevention are among the major primary and secondary sources referred for preparing this report.Read the full report: https://www.reportlinker.com/p06010023/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Go here to see the original:
Animal Genetics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product, Genetic Material, and Services and Geography. -...

Read More...

Fionas genetics are hugely valuable in species rebound – WLWT Cincinnati

January 29th, 2021 2:52 am

Fiona the hippopotamus could play a major role in her species' rebound. The world-famous hippo, who turns 4 this week at the Cincinnati Zoo, has genetics that are pretty valuable, her zookeepers said. She could play a critical role in bringing back a threatened species. Hippos are listed as a vulnerable, meaning they face a high risk of extinction in the wild. Officially, threatened species are those listed as critically endangered, endangered or vulnerable. Hippos are listed as vulnerable due to widespread poaching for meat and ivory, as well as human encroachment. It is the eventual goal to have Fiona breed in an effort to increase her species' numbers, but the timeline on when she will be able to breed remains murky.We anticipate that she will not be sexually mature until about 5 or 6 years old maybe even later than that because Fiona was a preemie, said Wendy Rice, head keeper of Africa Department at Cincinnati Zoo.Fiona was thrust into the spotlight due to her remarkable survival story. Born six weeks premature at the Cincinnati Zoo on Jan. 24, 2017, Fiona weighed only 29 pounds at birth 25 pounds less than the lowest recorded birth weight for her species. But she has rebounded from near-death, now weighing a whopping 1,600 pounds, consistent with a normal hippo her age. Fiona has a long way to go until shes considered full grown. But shes on track and making gains every day, Rice said.Already, Cincinnati's once-baby hippo has reached a certain level of maturity. And, when she's ready, Fiona will likely attempt to breed.Her fate and her love interest will likely be determined by the Hippo Species Survival Plan, a cooperation of all zoos across the United States that house hippos and breed them. The group shares information about captive populations in order to maintain genetic diversity.With Fiona being Henrys only living offspring, her genetics are fairly valuable in that theyre not well represented in the population that we have," Rice said. "Its very likely that she will get a recommendation to breed someday.So what happens then? It's highly unlikely that Fiona would move away from Cincinnati, Rice said. Instead, expect a male suitor to arrive in the Queen City.If and when she gets a recommendation for a breeding partner, theres a really good chance that the boy would have to come to Cincinnati. We do not want to have our princess leave Cincinnati, and the whole city would probably riot if she moved away.But we're still talking at least a year -- probably more -- down the road. In the meantime, Fiona will focus on growing. Right now, Rice said Fiona is probably the human equivalent of a pre-teen girl. She's growing out of her sassy phase and becoming more and more independent of her mother. In the past, wherever Bibi was, thats where Fiona was. Just this past year, shes gotten a little bit braver and bolder. Shes also starting to read boundaries a little bit better with mom. She was pushing the envelope, trying to see what she could get away with. But shes kind of settled down a bit and matured, and she can now read mama really well, Rice said. Even as the hippo matures, Rice said her personality is here to stay.Shes still full of personality and shell still come out here and put a show on for her guests," Rice said." Shell come right up to the glass and make eye contact with people. She understands that theyre here for her and that shes kind of a big deal. I think she appreciates her fandom and tries to give them the best experience possible.

Fiona the hippopotamus could play a major role in her species' rebound.

The world-famous hippo, who turns 4 this week at the Cincinnati Zoo, has genetics that are pretty valuable, her zookeepers said. She could play a critical role in bringing back a threatened species.

Hippos are listed as a vulnerable, meaning they face a high risk of extinction in the wild. Officially, threatened species are those listed as critically endangered, endangered or vulnerable. Hippos are listed as vulnerable due to widespread poaching for meat and ivory, as well as human encroachment.

It is the eventual goal to have Fiona breed in an effort to increase her species' numbers, but the timeline on when she will be able to breed remains murky.

We anticipate that she will not be sexually mature until about 5 or 6 years old maybe even later than that because Fiona was a preemie, said Wendy Rice, head keeper of Africa Department at Cincinnati Zoo.

Fiona was thrust into the spotlight due to her remarkable survival story. Born six weeks premature at the Cincinnati Zoo on Jan. 24, 2017, Fiona weighed only 29 pounds at birth 25 pounds less than the lowest recorded birth weight for her species.

But she has rebounded from near-death, now weighing a whopping 1,600 pounds, consistent with a normal hippo her age.

Fiona has a long way to go until shes considered full grown. But shes on track and making gains every day, Rice said.

Already, Cincinnati's once-baby hippo has reached a certain level of maturity. And, when she's ready, Fiona will likely attempt to breed.

Her fate and her love interest will likely be determined by the Hippo Species Survival Plan, a cooperation of all zoos across the United States that house hippos and breed them. The group shares information about captive populations in order to maintain genetic diversity.

With Fiona being Henrys only living offspring, her genetics are fairly valuable in that theyre not well represented in the population that we have," Rice said. "Its very likely that she will get a recommendation to breed someday.

So what happens then? It's highly unlikely that Fiona would move away from Cincinnati, Rice said. Instead, expect a male suitor to arrive in the Queen City.

If and when she gets a recommendation for a breeding partner, theres a really good chance that the boy would have to come to Cincinnati. We do not want to have our princess leave Cincinnati, and the whole city would probably riot if she moved away.

But we're still talking at least a year -- probably more -- down the road. In the meantime, Fiona will focus on growing.

Right now, Rice said Fiona is probably the human equivalent of a pre-teen girl. She's growing out of her sassy phase and becoming more and more independent of her mother.

In the past, wherever Bibi was, thats where Fiona was. Just this past year, shes gotten a little bit braver and bolder. Shes also starting to read boundaries a little bit better with mom. She was pushing the envelope, trying to see what she could get away with. But shes kind of settled down a bit and matured, and she can now read mama really well, Rice said.

Even as the hippo matures, Rice said her personality is here to stay.

Shes still full of personality and shell still come out here and put a show on for her guests," Rice said." Shell come right up to the glass and make eye contact with people. She understands that theyre here for her and that shes kind of a big deal. I think she appreciates her fandom and tries to give them the best experience possible.

More here:
Fionas genetics are hugely valuable in species rebound - WLWT Cincinnati

Read More...

Digbi Health’s gut-microbiome and genetic-based obesity management program now allows 60,000 Doctors and Providers in Blue Shield of California’s…

January 29th, 2021 2:52 am

MOUNTAIN VIEW, Calif., Jan. 26, 2021 /PRNewswire/ --Digbi Health, the first company with a clinically proven genetics and gut-microbiome based program to safely and sustainably treat and manage obesity and associated inflammatory gut, skin and cardiometabolic health issues, is now available to Blue Shield of California members, as a fully covered program, on the health plan'sWellvolution platform.

It's the first time over 60,000 physicians and clinicians practicing in California in the Blue Shield of California's network can prescribe a weight-loss program personalized on a person's genetic, gut microbiome and lifestyle. Through the Digbi Health solution, patients are supported by a team of caregivers, led by a physician and care experts trained in nutrition, cognitive behavior therapy, genetics and gut microbiome. Blue Shield of California offers access to Digbi Health through the Wellvolution platform as a fully covered program to members who qualify.

The Digbi Health Precision Care Network (PCN) is a network of physicians practicing precision medicine. As part of that network, physicians get marketing resources to educate their patients about Digbi Health on the Wellvoution platform, access to their patient's dashboard, with patient approval, and additional support from the Digbi Health care concierge team to support their patients between visits to help improve patient outcomes. Digbi Health program members without a physician can also get referred to a specialist in the PCN.

"The development of cardiovascular disease is a matter of genetic predisposition and gut microbiome composition interacting with acquired conditions, and factors such as diet, exercise, and exposure to damaging elements," said Cynthia Thaik, MD. Harvard-trained cardiologist at the Holistic Healing Heart Center and Digbi Health PCN member.

"I have already prescribed Digbi Health to a patient covered by Blue Shield of California for pre-diabetes and hypertension," she added.

Blue Shield of California is taking the lead on personalized and preventive care for their members.

Among participants participating in Wellvolution:

"We are an innovative telehealth company that supports overburdened physicians by redefining care for 100 million Americans who struggle under one-size-fits-all digital health programs, weight loss diets and stigma of "poor self-control" while fighting obesity and associated inflammatory comorbidities," said Ranjan Sinha, CEO and founder of Digbi Health.

About Digbi Health Precision Care NetworkOur network includes healthcare providers from all specialties and practice settings throughout the U.S., including bariatric surgeons, internal medicine, family medicine, chiropractitioners, nutritional experts, and others in the lifestyle and integrative medicine space using genetics, nutrigenomics, gut microbiome and lifestyle risk to treat the complexity of the multifactorial disease of obesity and its' related medical conditions. Providers can sign-up to the network at no charge here.

About Digbi HealthDigbi Health is a first-of-its-kind precision digital therapeutics company that offers a prescription-grade digitally enabled personalized obesity and obesity related gut, skin disorders, hypertension and other cardiometabolic health management programs based on an individual's gut biome, genetic risks, blood markers, and lifestyle factors. Digbi Health and members of its physician network are committed to empowering people to take control of their own health and wellness. Digbi Health is prescribed by doctors, health care providers, and insurance companies.

SOURCE Digbi Health

See the article here:
Digbi Health's gut-microbiome and genetic-based obesity management program now allows 60,000 Doctors and Providers in Blue Shield of California's...

Read More...

Research reveals genetic response of ocean warming and acidification in American lobster – UMaine News – University of Maine – University of Maine

January 29th, 2021 2:52 am

A team of researchers from the University of Maine Darling Marine Center in Walpole, Bigelow Laboratory for Ocean Sciences in East Boothbay and Maine Department of Marine Resources in West Boothbay Harbor recently published their research on the effects of ocean warming and acidification on gene expression in the earliest life stages of the American lobster.

The work was published in the scientific journal Ecology and Evolution with collaborators from the University of Prince Edward Island and Dalhousie University in Canada.

Leading the study was recent UMaine graduate student Maura Niemisto, who received her masters degree in marine science. Co-authors on the journal article were her advisers Richard Wahle, research professor in UMaines School of Marine Sciences and director of the Lobster Institute, and David Fields, senior research scientist at Bigelow Laboratory for Ocean Sciences.

Co-authors Spencer Greenwood of the University of Prince Edward Island and Fraser Clark of Dalhousie University brought the genetic expertise to the study. Jesica Waller of the Maine Department of Marine Resources conducted some of the initial studies that led to Niemistos experiments, also in the laboratories of Wahle and Fields.

The teams experiments examined the gene regulatory response of postlarval lobsters to the separate and combined effects of warming and acidification anticipated by the end of the 21st century. They found that genes regulating a range of physiological functions, from those controlling shell formation to the immune response, are either up- or down-regulated. Importantly, they observed that the two stressors combined induced a greater gene regulatory response than either stressor alone.

The results from the study indicate that changes in gene expression of postlarval lobster may act as a mechanism to accommodate rapid changes in the ocean environment. Niemisto noted that there is still need for further study to determine how rapidly populations of the species may be able to adapt to changing conditions. To better understand how gene regulation in response to environmental changes functions within the species, we should look at subpopulations and multigenerational studies to determine the extent of species capacity to respond to altered environmental conditions.

Mauras study reveals some of the hidden mechanisms species employ minute to minute and hour to hour at the cellular level to function normally in a variable environment, said Wahle. We need to gain these insights as we take on the larger challenge of understanding how species adapt on the much larger time scale of decades.

According to the National Marine Fisheries Service, the American lobster fishery is the most valuable in North America. The species holds particular socioeconomic importance in the Gulf of Maine, where sea surface temperatures are increasing at a rate faster than most of the worlds oceans and waters are more susceptible to higher rates of acidification.

The center of the American lobster range has been shifting northward in response to warming ocean temperatures. However, little is known about how the species will respond to the combined effects of increasing ocean temperatures and acidification. This study is a first step in answering that question. The species earliest life stages are thought to be especially vulnerable to these climate related challenges.

The research was supported by a grant from the NOAAs Ocean Acidification Program and the National Sea Grant Program. Additional funding for student internships came from Bigelow Laboratorys Research Experience for Undergraduates program, supported by the National Science Foundation.

Contact: Matt Norwood, matthew.norwood@maine.edu; 207.563.8220

See more here:
Research reveals genetic response of ocean warming and acidification in American lobster - UMaine News - University of Maine - University of Maine

Read More...

Huskypoo puppy donated to teen with rare genetic disorder – Tampa Bay Times

January 29th, 2021 2:52 am

LARGO There are roughly up to 500 boys in the world and only boys who suffer from NEMO deficiency syndrome, a rare genetic illness that affects the nervous system and leave one susceptible to infections.

Peyton Kudrnovsky and his brother Trevor are among them. Two weeks ago, 15-year-old Peyton lost his Golden Retriever Axl Rose, who had been a part of the family for 12 years. Axl always sat by Peytons side during his infusions.

Then on Saturday, his family brought home a new four-legged member of the family: Toby.

Toby is a Huskypoo a mix between a Siberian Husky and a poodle donated to the 15-year-old by the Petland Largo store.

Petland Largo manager Miranda Schimenek said they decided to donate Toby after they learned about Peytons story and the loss of Axl. The store at 10289 Ulmerton Road will also provide veterinary care and training for Toby, according to a press release.

The loss of Axl was particularly hard for Peyton, said his mother Tatiana Lee. Axl had been there every step of the way through the 15-year-olds medical treatments, she said. Axl was given to Peyton by his stepfather, Kyle Resler. But the stepfather died two years ago from cancer.

Over two years ago, we lost a loved one to terminal cancer, the mother said in a statement. Peyton had formed a very close bond with him. He was Peytons support system through the illness and we all miss Kyle very much.

They also miss Axl, who helped the family after they lost their stepfather.

He was there for us through the loss of my sons stepdad, Kyle, and would sit by Peyton as he had his infusions each week he was our rock, and we know he is looking down on us, she said. Toby will be an incredible addition to our family and I cannot thank Petland enough for their incredibly gracious gesture.

Read the original post:
Huskypoo puppy donated to teen with rare genetic disorder - Tampa Bay Times

Read More...

Spatial patterns and conservation of genetic and phylogenetic diversity of wildlife in China – Science Advances

January 29th, 2021 2:52 am

Abstract

Genetic diversity and phylogenetic diversity reflect the evolutionary potential and history of species, respectively. However, the levels and spatial patterns of genetic and phylogenetic diversity of wildlife at the regional scale have largely remained unclear. Here, we performed meta-analyses of genetic diversity in Chinese terrestrial vertebrates based on three genetic markers and investigated their phylogenetic diversity based on a dated phylogenetic tree of 2461 species. We detected strong positive spatial correlations among mitochondrial DNA-based genetic diversity, phylogenetic diversity, and species richness. Moreover, the terrestrial vertebrates harbored higher genetic and phylogenetic diversity in South China and Southwest China than in other regions. Last, climatic factors (precipitation and temperature) had significant positive effects while altitude and human population density had significant negative impacts on levels of mitochondrial DNA-based genetic diversity in most cases. Our findings will help guide national-level genetic diversity conservation plans and a post-2020 biodiversity conservation framework.

Biodiversity loss and conservation are among the most concerning global issues. The Convention on Biological Diversity (CBD) was established to develop national strategies for the conservation and sustainable use of biological diversity. An endangerment status assessment of worldwide vertebrates showed that approximately 20% of vertebrates have become threatened (1). In China, the situation is even worse: 21.4% of vertebrates are threatened, including 43.1% of amphibians, 29.7% of reptiles, 26.4% of mammals, 20.4% of fishes, and 10.6% of birds (2). Thus, it is urgent to protect biodiversity regionally and globally. As the most fundamental dimension of biodiversity, genetic diversity is a key basis for species survival and ecosystem functions (3). Higher genetic diversity means higher evolutionary potential and a greater ability to respond to environmental changes (4). An increasing number of studies have shown that genetic factors play a critical role in species endangerment and extinction (57). Thus, assessment and protection of genetic diversity are becoming essential and high-priority strategies for biodiversity conservation (4). However, under the current CBD framework, the goal proposed for genetic diversity focuses mainly on the conservation of farmed and domestic animals and cultivated plants and neglects that of wild animals and plants, which would overlook genetic erosion and harm the evolutionary potential of wildlife (8). Therefore, to better conserve the genetic diversity of wildlife, it is necessary to assess genetic diversity at regional and global scales for use in the scientific designs of natural protected areas and biodiversity conservation strategies. Miraldo et al. (9) presented the first global distribution of genetic diversity for mammals and amphibians using mitochondrial cytochrome b (Cytb) and cytochrome oxidase subunit I (Co1) gene sequences. However, the grid cell size (~150,000 km2) that they used was so large that it was difficult to determine the national- or regional-level pattern of genetic diversity in detail, including in China.

Phylogenetic diversity is the sum of phylogenetic branch lengths for all of the species in an area (10). Phylogenetic diversity measures the time scale of species evolution and reflects the evolutionary history of species (11), which contributes to the selection of biodiversity conservation priority areas (1214). Higher phylogenetic diversity excluding the effect of taxonomic richness indicates a higher proportion of distantly related and anciently diverged taxa (11, 15). Previous studies have shown that regions with higher phylogenetic diversity may not necessarily have higher species diversity, which would result in neglecting the conservation of the regions (11, 16). In this case, the conservation of older evolutionary lineages might be neglected. Thus, monitoring the level and spatial distribution of phylogenetic diversity is also important for effective conservation of biodiversity.

China is one of the countries with the richest biodiversity in the world, harboring more than 3000 terrestrial vertebrates (2). In recent years, with the development of molecular genetics, genetic diversity of many species has been assessed and numerous DNA sequences have been accumulated. In this study, we focus on the patterns of genetic and phylogenetic diversity in Chinese terrestrial vertebrates, using meta-analyses of a large published dataset and a robust dated phylogenetic tree as well as species distribution. We aim to (i) reveal whether positive spatial correlation existed among species richness, genetic diversity, and phylogenetic diversity; (ii) identify hotspot regions of high genetic diversity and high phylogenetic diversity; and (iii) explore the influences of abiotic (precipitation, temperature, and altitude) and biotic (human population) factors on the levels of genetic and phylogenetic diversity. We found that, on the whole, species richness predicted phylogenetic diversity and mitochondrial DNA-based genetic diversity in a positive direction, and higher phylogenetic diversity predicted higher genetic diversity. We identified that the terrestrial vertebrates in South China and Southwest China harbored higher genetic and phylogenetic diversity than in other regions, and central South China was identified as an evolutionary museum, while the Hengduan Mountains was identified as an evolutionary cradle. We also revealed that both mean annual precipitation and temperature had significant positive effects, while altitude and human population density had significant negative impacts on levels of mitochondrial DNA-based genetic diversity in most cases. Our findings provide insights into the spatial patterns and influencing factors of genetic and phylogenetic diversity at a regional scale.

We surveyed the population-level genetic diversity data of Chinese terrestrial vertebrates (mammals, birds, reptiles, and amphibians) based on three molecular markers (mitochondrial Cytb gene sequence, mitochondrial D-loop sequence, and nuclear microsatellites). A total of 287 terrestrial vertebrate species (103 mammals, 59 birds, 31 reptiles, and 94 amphibians) were assessed for population-level genetic diversity with at least one molecular marker, accounting for 9.3% of the 3075 terrestrial vertebrates distributed in China (figs. S1 to S4 and tables S1 to S9). Two unbiased genetic diversity indices, nucleotide diversity () for the Cytb and D-loop sequences and expected heterozygosity (HE) for microsatellite, were used as measures of population-level genetic diversity. In this study, the Cytb-, D-loop, and microsatellite-based genetic diversity measures were analyzed separately (tables S1 to S9). Furthermore, the species-level genetic diversity for three genetic markers was obtained by averaging the population-level genetic diversity values (tables S10 to S12).

The species-level phylogenetic diversity of Chinese terrestrial vertebrates was surveyed on the basis of the coding sequences of five mitochondrial genes (Cytb, Co1, Nd1, 12S rRNA, and 16S rRNA). A total of 2461 terrestrial vertebrates were assessed for phylogenetic diversity with at least one available mitochondrial gene sequence, accounting for 80% of the Chinese terrestrial vertebrates (figs. S5 to S7 and table S13). On the basis of a constructed maximum likelihood phylogenetic tree and 391 available divergence times from the TimeTree database (table S14), we estimated the divergence times of these vertebrates. The results showed that the amphibians first diverged from the fishes and then the reptiles evolved from the amphibians. Both the mammals and birds evolved from the reptiles, with the mammals diverging first. These results are consistent with the general conclusion about the divergence order of the terrestrial groups (17). In this study, we used divergence time as the measure of phylogenetic diversity for further analysis.

We first divided the map of China into 0.5 0.5 (~50 km by 55 km) grid cells and then calculated the species richness, genetic diversity, and phylogenetic diversity within each grid cell. The spatial correlation tests showed that the genetic diversity measures based on mitochondrial Cytb and D-loop sequences were significantly correlated [correlation coefficient (r) = 0.385, P = 0.012]. However, no significant correlation was observed for Cytb versus microsatellites (r = 0.128, P = 0.475) and for D-loop versus microsatellites (r = 0.084, P = 0.463) (fig. S8 and table S15). The inconsistencies in spatial correlations among the three genetic markers were most likely due to different measure rationales (nucleotide diversity versus expected heterozygosity) and evolutionary rates (slowly versus rapidly evolving). The differences in correlation among the different markers were similar to that of Miraldo et al. (9).

The tests for spatial correlations between genetic diversity and species richness revealed a significant positive correlation for Cytb genetic diversity (r = 0.728, P = 0.008), and a marginally significant correlation for D-loop genetic diversity (r = 0.320, P = 0.072) (Fig. 1, A and B). These results were consistent with those of global terrestrial mammals (18) and global marine and freshwater fishes (19). However, a nonsignificant correlation for microsatellite genetic diversity (r = 0.138, P = 0.499) was detected (Fig. 1C and table S15), which was similar to AFLP marker-based genetic diversity assessment of alpine plant communities (20). The differences in correlation showed that the widely discussed correlation relationship between genetic and species diversity was genetic marker dependent.

(A to C) Correlation tests between species richness (SR) and Cytb-, D-loop, and microsatellite-based genetic diversity (GD). (D) Correlation test between SR and phylogenetic diversity (PD). (E to G) Correlation tests between PD and Cytb-, D-loop, and microsatellite-based GD.

The tests for spatial correlations between genetic diversity and phylogenetic diversity showed a significant positive correlation for Cytb (r = 0.722, P = 0.013) and a marginally significant positive correlation for D-loop (r = 0.306, P = 0.089) (Fig. 1, E and F). The results were similar to those of global terrestrial mammals (18). However, the correlation was not significant for microsatellites (r = 0.123, P = 0.566) (Fig. 1G and table S15). In addition, we selected a set of abundant terrestrial vertebrate species with a threatened status rank of LC (Least-Concern) (table S16) and tested the spatial correlations between genetic and phylogenetic diversity. The results were similar to those for all the terrestrial vertebrates (table S17).

A significant positive correlation was detected between phylogenetic diversity and species richness (r = 0.99, P < 0.001) (Fig. 1D and table S15), implying that the regions with high species richness often had high phylogenetic diversity. The significant positive correlation pattern between phylogenetic diversity and species richness may be common, as shown in different large-scale analyses focusing on birds, mammals, and angiosperms (16, 18, 21).

It is generally accepted that Chinas zoogeographical regionalization is divided into the Palaearctic and Oriental realms, including seven zoogeographical regions (22, 23). The Palaearctic realm includes the Northeast China, North China, Inner Mongolia-Xinjiang, and Qinghai-Tibet Plateau regions, while the Oriental realm consists of the Southwest China, Central China, and South China regions. We mapped the genetic diversity data onto the zoogeographical region map of China using a grid size of 0.5 0.5. Overall, the terrestrial vertebrates distributed in the Oriental realm had higher genetic diversity than those in the Palaearctic realm for all three markers (Fig. 2, A to C; fig. S9; and table S18). In the case of zoogeographical regions, the vertebrates in South China harbored the highest genetic diversity for Cytb and microsatellites, suggesting a hotspot region of genetic diversity, whereas those in North China had the lowest genetic diversity for D-loop and microsatellites (table S18). In addition, the Southwest China and west Central China harbored relatively high genetic diversity. The spatial pattern of species richness across the Palaearctic and Oriental realms was similar to that of genetic diversity (Fig. 2D). However, within the zoogeographical regions, the spatial patterns of species richness were somewhat different from those of genetic diversity. The South China region had the highest species richness, whereas the Qinghai-Tibet Plateau and Inner Mongolia-Xinjiang regions harbored the lowest species richness (Fig. 2D). These results suggest that regions with low species richness do not necessarily have low genetic diversity, such as the Qinghai-Tibet Plateau, which should be given more conservation attention. To determine the possible effects of different sample sizes of the grid cells, we examined the frequency distribution of the proportion of species with surveyed genetic diversity data in the grid cells based on the classification of seven zoogeographical regions and found similar frequency distributions on the whole across the seven regions (figs. S10 to S12).

Northeast China (NE), North China (NC), Inner Mongolia-Xinjiang (IX), Qinghai-Tibet Plateau (QT), Southwest China (SW), Central China (CC), and South China (SC). The red line indicates the boundary between the Palaearctic and Oriental realms. (A and B) Spatial patterns of Cytb- and D-loopbased GDs. measured by nucleotide diversity. (C) Spatial pattern of microsatellite-based GD measured by expected heterozygosity. (D) Spatial pattern of SR measured by number of species.

The province-level distributions of genetic diversity based on the three markers demonstrated similar patterns on the whole (figs. S13 and S14). The terrestrial vertebrates distributed in Yunnan, Guangxi, Sichuan, and Guizhou provinces harbored the highest genetic diversity. In contrast, the terrestrial vertebrates distributed in Shanxi, Shandong, Hebei, Liaoning, Jilin, Heilongjiang, and part of Xinjiang had lower genetic diversity. The terrestrial vertebrates in Qinghai and Tibet had intermediate genetic diversity. These results could help guide province-level conservation plans for genetic diversity.

The terrestrial vertebrates in the Oriental realm had significantly higher phylogenetic diversity (PD = 10,390.25 2029.43) than those in the Palaearctic realm (PD = 4942.60 1402.09) (Fig. 3, A and B). The terrestrial vertebrates in South China harbored the highest phylogenetic diversity (PD = 12,327.46 2111.27), and those in Central China and Southwest China had the second highest phylogenetic diversity. The terrestrial vertebrates on the Qinghai-Tibet Plateau had the lowest phylogenetic diversity (PD = 3936.66 1162.35) (Fig. 3B and table S18). The province-level distribution of phylogenetic diversity showed a clear pattern, in which the terrestrial vertebrates in south China had notably higher phylogenetic diversity than those in north China (fig. S15). Specifically, the vertebrates in Yunnan and Guangxi provinces had the highest phylogenetic diversity, and those in Tibet, Xinjiang, and Qinghai had the lowest phylogenetic diversity (fig. S15). These results could help guide province-level conservation plans for phylogenetic diversity.

(A) A dated phylogenetic tree of Chinese terrestrial vertebrates based on five mitochondrial genes (Cytb, Co1, Nd1, 12S rRNA, and 16S rRNA). Ma, million years. (B) Spatial pattern of PD measured by species divergence time. The red line indicates the boundary between the Palaearctic and Oriental realms. (C) Areas with significantly higher or lower PD after controlling for the confounding effect of SR. The red line indicates the boundary between the Palaearctic and Oriental realms.

As shown by the correlation analysis above, the phylogenetic diversity pattern was highly correlated with the species richness pattern (Fig. 1D). To control for the confounding effect of species richness, we detected areas with significantly higher or lower phylogenetic diversity than expected using a randomization method. The result showed that significantly higher phylogenetic diversity occurred in the central South China region, mainly including Hainan and Guangxi provinces, suggesting that these areas harbored many older terrestrial vertebrate lineages, serving as an evolutionary museum (Fig. 3C and fig. S16) (9). This result is similar to that for the phylogenetic diversity of genus-level angiosperms in China, in which the top 5% highest phylogenetic diversity and standard effective size of phylogenetic diversity were mainly located in Guangdong, Guangxi, Guizhou, and Hainan provinces (15). These results suggested that the above areas are phylogenetic diversity hotspots not only for terrestrial vertebrates but also for angiosperms in China, which deserve more conservation efforts. In contrast, significantly lower phylogenetic diversity occurred in the Southwest China region, i.e., the Hengduan Mountains, suggesting that these areas were the centers of recent speciation events and thus contained many younger lineages, serving as an evolutionary cradle (Fig. 3C and fig. S16) (15, 24). This divergence pattern is similar to that of a study on global terrestrial birds (16).

The above correlation results showed that the mitochondrial DNA-based genetic diversity was strongly correlated with species richness. Therefore, to reveal the effects of abiotic and biotic factors on genetic diversity, we performed the semi-part spatially explicit generalized linear mixed modeling (spaGLMM) analysis by regressing genetic diversity against species richness and then using the residuals of models to evaluate the effects of abiotic (mean annual precipitation, mean annual temperature, and altitude) and biotic (human population density) factors. The results showed that most of the genetic diversity measures were well predicted by these factors (Table 1). In detail, mean annual precipitation had a significant positive effect on Cytb-based genetic diversity; mean annual temperature had a significant positive effect on D-loopbased genetic diversity; and altitude and human population density had significant negative impacts on Cytb- and D-loopbased genetic diversity (Table 1). In addition, the spaGLMM analysis with the species richness included as an explanatory variable gave similar results to the semi-part spaGLMM analysis (table S19). Because the relationships between most of the factors and microsatellite-based genetic diversity were different from theoretically expected, here we did not discuss microsatellite-related results.

MAP, mean annual precipitation; MAT, mean annual temperature; ALT, mean altitude; HPD, human population density.

Because the phylogenetic diversity was very strongly correlated with species richness, we also performed the semi-part spaGLMM analysis for phylogenetic diversity. The results showed that the above abiotic and biotic factors had no significant impacts on phylogenetic diversity (Table 1), suggesting that the species richness had a much higher effect on phylogenetic diversity compared to other factors. To test this, we performed the spaGLMM analysis with species richness as an independent variable. The results showed that the importance of species richness was far more than those of other factors, indicating that phylogenetic diversity was mainly affected by species richness (table S19).

This is the first study to assess the correlation between genetic diversity and phylogenetic diversity for all the terrestrial vertebrate groups at a large spatial scale. The findings revealed a significant correlation between genetic and phylogenetic diversity for Cytb-based genetic diversity measure and a marginally significant correlation for D-loopbased measure at a grid cell scale, demonstrating the important role of phylogenetic diversity in predicting level of genetic diversity. In addition, we also found a significant positive correlation between genetic diversity and species richness for Cytb-based genetic diversity measure and a marginally significant correlation for D-loopbased measure. However, no significant correlations were detected between genetic diversity and phylogenetic diversity (or species richness) for microsatellite-based measure, suggesting that these correlations are genetic marker dependent.

Our study is also the first region-level survey and assessment of the genetic and phylogenetic diversity of Chinese terrestrial vertebrates that demonstrated the spatial distribution pattern of diversity and identified the regions of high and low genetic/phylogenetic diversity. The spatial patterns showed that the terrestrial vertebrates in South China and Southwest China harbored not only higher genetic diversity but also higher phylogenetic diversity, highlighting the high conservation priority for these hotspot regions. We also identified key areas with significantly higher or lower phylogenetic diversity after controlling for the effects of species richness and discerned the evolutionary museum and cradle for Chinese terrestrial vertebrates. In particular, we found inconsistencies among the regions in terms of genetic and species diversity. Although the terrestrial vertebrates on the Qinghai-Tibet Plateau had the lowest species richness, they had intermediate genetic diversity, possibly because of less human activity and heterogeneous abiotic effects in this region. The terrestrial vertebrates in North China and Northeast China, which are exposed to more human activity and located in north further in latitude, harbored intermediate species richness but lower genetic diversity. These results were supported by the semi-part spaGLMM analyses, which revealed that abiotic (precipitation, temperature, and altitude) and biotic factors (human population) played important roles in the spatial patterns of genetic diversity.

We investigated the effects of abiotic and biotic factors driving the spatial patterns of genetic and phylogenetic diversity at a grid cell scale. On the whole, the effects of these factors on Cytb- and D-loopbased genetic diversity were consistent with ecological and evolutionary expectations. Mean annual precipitation and temperature had significant positive effects on genetic diversity, because higher precipitation and temperature most likely provide more suitable conditions for species survival, population expansion, and speciation. In contrast, altitude had significant negative impacts on genetic diversity, because higher elevation means harsher living conditions especially for terrestrial vertebrates. For biotic factor, human population density had significant negative impacts on genetic diversity, because higher density means more human activities and more possible interference with wildlife and their habitats.

Our study summarizes the findings of genetic/phylogenetic diversity studies, revealing the basic background of genetic resources in Chinese terrestrial vertebrates, which could facilitate genetic resource protection under the CBD framework and guide future genetic/phylogenetic diversity research and conservation. In addition, compared with the total number of Chinese terrestrial vertebrates, the number of species with surveyed genetic diversity data is relatively small. To better conserve genetic diversity, scientists and managers should cooperate to perform genetic diversity surveys for more species, especially those with an unclear genetic status. Furthermore, the genetic and phylogenetic diversity of freshwater and marine vertebrates should be surveyed and assessed to protect gradually decreasing aquatic genetic resources. Last, our study is the first to use nuclear microsatellite markers to assess large-scale genetic diversity pattern and explore the relationship between genetic and phylogenetic diversity. However, it is worth noting that microsatellite-based correlation and model analyses produced different results from those based on mitochondrial DNA, which cautions us to carefully interpret results from different genetic markers.

We retrieved published literatures of population-level genetic diversity studies from public academic databases. For the English literature, we searched the Web of Science database (http://apps.webofknowledge.com/) using the search rule TS = (species Latin name OR species English name) AND TS = genetic diversity AND TS = population. For the Chinese literature, we searched the CNKI database (www.cnki.net), CQVIP database (www.cqvip.com), and Chinese Science Citation Database (http://sciencechina.cn) using the search rule species Latin name AND genetic diversity. Then, to search the literature as comprehensively as possible, we searched only the species Latin name again for species without related references or with few related references.

We screened the retrieved literature following several steps. First, we used only the literature about wild animal studies and discarded the literature studying captive populations. Second, we focused on population-level studies based on microsatellite, mitochondrial Cytb, or D-loop markers. These three markers have been widely used in population genetics and phylogeographic studies of vertebrates. For microsatellite-based studies, we extracted the expected heterozygosity (HE) values for each population of species as the measure of microsatellite genetic diversity. HE is an unbiased measure and thus insensitive to small sample sizes (25). For mitochondrial Cytb gene and D-loop sequence-based studies, we extracted Neis nucleotide diversity () values for each population of species as the measure of Cytb or D-loop genetic diversity (26). is also unbiased and thus insensitive to small sample sizes (26). If the same population had more than one HE or from different references, we used the mean value as the genetic diversity measure of this population. Last, on the basis of population-level genetic diversity data, we estimated species-level genetic diversity by averaging the population-level genetic diversity values (9). Mean genetic diversity metric has been widely applied in large-scale studies (9, 18, 19).

In total, we compiled a dataset of 287 terrestrial vertebrates, which included 103 mammals, 59 birds, 31 reptiles, and 94 amphibians, accounting for 15.6, 4.1, 6.7, and 18.6% of the respective total numbers of species (figs. S1 and S2). Overall, the assessment proportions for genetic diversity of mammals and amphibians were higher than those of birds and reptiles, with the proportion of birds being the lowest. The number of terrestrial vertebrate species with population-level genetic diversity data based on microsatellite marker (n = 151) was higher than those based on Cytb gene (n = 142) and D-loop (n = 105), accounting for 4.9, 4.6, and 3.4% of the 3075 Chinese terrestrial vertebrates, respectively (figs. S3 and S4).

Sequences of five mitochondrial genes (Cytb, Co1, 12S rRNA, 16S rRNA, and Nd1) were used to reconstruct the phylogeny of Chinese terrestrial vertebrates. The sequences of the five mitochondrial genes were searched in GenBank with the following steps. First, the available mitochondrial reference genomes were downloaded, and the corresponding coding sequences of these genes were extracted. Then, the available coding sequences for the remaining species were directly downloaded from GenBank using the species Latin name and gene name. If more than one sequence was available for the same locus of a species, the sequence with a length similar to that of the corresponding gene was selected. Last, the short genes whose coding sequence length was <300 base pairs were discarded from the dataset. After these steps, we compiled a total of 2461 species including 573 mammals, 1170 birds, 359 reptiles, and 359 amphibians, representing 87.0, 81.0, 77.2, and 71.0% of the respective total numbers of species. Our dataset covered 46 orders, 204 families, and 847 genera. For each gene, the coding sequences of 973 species were extracted from their mitochondrial genomes, while others were directly downloaded from the GenBank database. The numbers of species with Cytb and Co1 sequences were higher than those with Nd1, 12S rRNA, and 16S rRNA sequences (fig. S7).

The coding sequences of each gene were concatenated and aligned by MAFFT (27) with default parameters, and the poorly aligned sites at the beginning and the end were trimmed. Then, the aligned sequences of these five genes were imported into SequenceMatrix software (28) to construct a supermatrix with the gaps treated as missing data. A phylogenetic analysis was performed on this supermatrix using the maximum likelihood method implemented in RAxML 8.2.12 (29) with the ASC_GTRGAMMA model and 1000 bootstrap replicates. Each gene was treated as a partition, and the zebrafish was used as outgroup. On the basis of this phylogenetic tree, we used the penalized likelihood method implemented in treePL (30) to date the divergence times of these vertebrates. A total of 391 available divergence times from TimeTree (31) were selected as calibration points for the dating analysis (table S14). The prime option and through analysis were implemented with optimal parameters.

On the basis of our dated phylogenetic tree and species distribution data, we calculated Faiths phylogenetic diversity of Chinese terrestrial vertebrates using the picante package (32) in R, as widely used in phylogenetic diversity studies (33). In this study, we used divergence time as the measure of phylogenetic diversity of each species.

The distributional ranges of terrestrial vertebrate species (including mammals, amphibians, reptiles, and birds) were derived from the IUCN spatial database (www.iucnredlist.org/resources/spatial-data-download). The range of each species was originally in a vectorized shapefile format and was rasterized into a grid system with a 0.5 0.5 resolution (~50 km by 55 km). We double-checked the rasterized maps to confirm that they matched the original vectorized distributional range maps. The resultant rasterized map of each species was always conservative relative to the original vectorized map, as many margins of species fragmented distributions might not have been recorded as the presence of the species in our 0.5 0.5 grid cells. This is because the areas of these margins were too small in the corresponding grid cells. The map of China used in this study was from Resource and Environment Science and Data Center (www.resdc.cn/data.aspx?DATAID=200). The Latin name of each species was checked to avoid potential synonyms. In total, our gridded distribution database included the occurrence records for 1941 species. After matching with the genetic and phylogenetic data, the final distribution dataset used for the diversity assessment included a total of 180 species for the genetic diversity analysis and 1685 species for the phylogenetic diversity analysis.

Climate data with a 2.5 spatial resolution were collected from the WorldClim database (https://worldclim.org/). We used the two most important climatic variables, mean annual temperature and mean annual precipitation that were calculated for the climate data from 1970 to 2000, as predictors of spatial patterns of genetic and phylogenetic diversity of terrestrial vertebrates in China. Human population density in 2010 in China (in persons per square kilometer) was derived from the Gridded Population of the World collection (https://sedac.ciesin.columbia.edu/data/collection/gpw-v4). Digital elevation data with a 2.5 spatial resolution in China were originally derived from the NASA Shuttle Radar Topographic Mission and downloadable from the WorldClim database. Because we mapped the genetic and phylogenetic diversity using a grid cell size of 0.5 0.5 for each variable (including altitude), we took the average of all values within each grid cell as the variables value for the grid cell.

In many cases in which biodiversity data are collected associated with spatial information (e.g., sampling location coordinates), conventional correlation tests are not valid because the assumption of total independence of samples is violated. For spatial biodiversity data, neighboring locations can present similar biodiversity features (e.g., genetic diversity or phylogenetic diversity as investigated here), which is a phenomenon known as spatial autocorrelation, resulting in nonindependent association of biodiversity information between neighboring locations. To this end, conventional correlation tests can be misleading. To cope with this issue, we used a modified t test to account for spatial autocorrelation (34, 35) when testing the spatial associations between genetic diversity, phylogenetic diversity, and species richness. The test is based on the adjustment of the sample correlation coefficient between the two spatially correlated quantities and requires the estimation of an effective sample size (degrees of freedom).

We performed spatial correlation tests between genetic diversity based on different markers, between genetic diversity and species richness, between genetic diversity and phylogenetic diversity, and between phylogenetic diversity and species richness. In addition, we selected a set of abundant terrestrial vertebrate species with a threatened status rank of LC (2) to further explore the relationship between genetic diversity and phylogenetic diversity. The set of abundant terrestrial vertebrates included 39 species for Cytb, 25 species for D-loop, and 45 species for microsatellite (table S16). We performed the correlation analyses for Cytb-, D-loop, and microsatellite-based genetic diversity separately.

We divided the map of China into 0.5 0.5 grid cells using R software. Then, we mapped the spatial distributional patterns of species richness, genetic diversity, and phylogenetic diversity based on the diversity values calculated for each grid cell. For species richness, we summed the total number of species occurring in the grid cell. For genetic diversity, we summed the genetic diversity values of each species present within the grid cell and divided the total value by the number of species surveyed in the grid cell, as used in (9). For phylogenetic diversity, we summed the divergence times of all species surveyed within the grid cell following the definition of Faiths phylogenetic diversity (10, 15).

To detect grid cells with significantly higher or lower phylogenetic diversity than expected controlling for the confounding effect of species richness, we used a randomization protocol (36). In detail, we first computed the phylogenetic diversity for each grid cell and divided this value by the species richness found in the cell. Then, we used a random swapping algorithm to randomize the species-site binary matrix while fixing the species richness of each grid cell and the range size of each species. The randomization procedure was repeated 1000 times, and the following effective size of phylogenetic diversity-species richness was computedZPD=ObsPDMean(RandPD)SD(RandPD)where ObsPD is the observed phylogenetic diversity-species richness ratio for each grid cell. RandPD represents the random phylogenetic diversity-species richness ratio calculated for each grid cell derived from the randomized species-site matrix. Mean(RandPD) and SD(RandPD) denote the mean and standard deviation of the 1000 random phylogenetic diversity-species richness ratio values, respectively. ZPD approximately followed a standard normal distribution; as such, at the significance level of 0.05, a grid cell was identified as having statistically significantly high phylogenetic diversity given the associated species richness if ZPD > 1.96. Conversely, a grid cell was identified as having statistically significantly low phylogenetic diversity given the associated species richness if ZPD < 1.96.

Species richness might have strong associations with genetic and phylogenetic diversity (37, 38). To explore the effects of factors affecting the spatial patterns of genetic and phylogenetic diversity of Chinese terrestrial vertebrates, we performed a semi-part spaGLMM implemented in the spaMM package (39) in the R environment (40), in which the influence of species richness on genetic or phylogenetic diversity was explicitly partialled out. To do so, we firstly constructed a spaGLMM model in which species richness is the only explanatory variable of genetic or phylogenetic diversity and then we used the residuals of this model for evaluating the impacts of other abiotic and biotic factors on genetic or phylogenetic diversity. In addition, to assess the effect of species richness on genetic and phylogenetic diversity, we also performed the spaGLMM analyses with the species richness as an explanatory variable as well as other factors.

For all the above spaGLMM analyses, a correlation matrix according to the Matrn correlation function was assumed and fitted on the basis of the longitude and latitude information of the center point of each grid cell when fitting the mixed model. The Matrn correlation function, containing a scale parameter and a smoothness parameter, is widely applied to model spatial correlation by including exponential and squared exponential models as special cases (41, 42). For the modeling results of semi-part spaMM analyses, when the confidence interval of the estimated coefficient for an explanatory variable was significantly deviated from zero, the variable was considered to have a significant effect on levels of genetic or phylogenetic diversity.

R. Frankham, J. D. Ballou, D. A. Briscoe, Introduction to Conservation Genetics (Cambridge Univ. Press, 2002).

D. J. Futuyma, Evolution (Oxford Univ. Press, 2013).

R. Z. Zhang, China Animal Geography (Science Press, 1999).

M. L. Stein, Interpolation of Spatial Data: Some Theory for Kriging (Springer Press, 2012).

Acknowledgments: We thank Jiekun He for providing the map of zoogeographical regionalization. Funding: This study was supported by the National Natural Science Foundation of China (31821001); the Strategic Priority Research Program of Chinese Academy of Sciences (XDB31000000); the Biodiversity Survey, Monitoring and Assessment Project of Ministry of Ecology and Environment of China (2019HB2096001006); the National Natural Science Foundation of China (31672319); the Youth Innovation Promotion Association, CAS (2016082); and the Special Research Assistant Program of CAS. Author contributions: F.W. conceived and supervised the project. Y.H., H.F., J.C., X.Z., H.W., B.Z., L.Y., X.H., X.S., T.P., W.W., and J.L. performed the data collection. Y.H., H.F., Y.C., J.C., M.W., W.Z., L.Y., and H.H. performed the data analysis. Y.H., H.F., and Y.C. wrote the manuscript with input from F.W. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

See the article here:
Spatial patterns and conservation of genetic and phylogenetic diversity of wildlife in China - Science Advances

Read More...

Tikun Olam-Cannbit have developed a revolutionary system for the characterization of genetic fingerprints in order to identify and track cannabis…

January 29th, 2021 2:52 am

TEL AVIV, Israel, Jan. 28, 2021 /PRNewswire/ --The company 'Tikun Olam Cannbit' (TASE: TKUN)is making history - The company have developed an in-house revolutionary genetic system for the identification and tracking of cannabis strains (cultivars and varieties), through the characterization of the genetic fingerprints based on the DNA sequence of each and every cannabis plant. True to its role, the system is called: Cannabis Genetic Fingerprinting, or 'CGF'.

Putting an end to the mess - the CGF system changes the rules of the game : The characterization of fingerprints by this system is being done by the genetic diagnosis of a variety of unique sequences along the cannabis plant's genome, based on a number of consecutive genetic technologies. The genetic fingerprint is actually a biological and totally natural barcode (Non-GMO), which accompanies the plant throughout its complete life cycle, and in some cases, into the final product.

The CGF system is expected to play as a substantial "game changer" in the cannabis industry, as well as set a standard in terms of strain's identification, genetic stability, uniformity (reducing the deviation ranges in the active ingredients profile), repeatability and thus resulting in improved 'Therapeutic Continuity', IP registration and protection, organization's strains bank management and tracking of cannabis strains in the future cannabis market.

This ability to identify strains accurately and independently has been considered for many decades as a "holy grail" of the cannabis world. A world comprising thousands of strains, with no ability to identify which is which in an objective manner, or to effectively track and monitor strains over time in the global space.

Till today, the identification of cannabis plants has been based on the characterization of its observable measured traits . Traits such as plant's height, color tone of the leaf, stem's diameter, the measured active ingredients profile and many more expressed and variable characteristics. However, the plant's traits are in fact varying, depending on hundreds of external varying factors, unrelated to the plant itself or its identity. Factors in the level of environmental conditions, cultivation methods, storage, as well as measurements and procedures. Factors such as lighting and radiation, fertilizers, humidity, pests, diseases, temperature, measurement tools, work methods and many other variable factors. Depending on these variables, the characteristics of the tested plant may also vary along with his identity, which is diagnosed accordingly.

Apart from the obvious use of the CGF system to identify unknown cannabis plants and hence also to identify different types of products, the company believes that based on this system, the process of registering strains as an IP rights, can also be substantially improved and streamlined.

The CGF system is currently in the commercialization phase which is expected to provide a cost effective, fast technical platform and to enable ongoing and big scale commercial use.

FOR MORE INFORMATION: Eliana Horenczyk [emailprotected]

SOURCE Tikun Olam Cannbit

Read more here:
Tikun Olam-Cannbit have developed a revolutionary system for the characterization of genetic fingerprints in order to identify and track cannabis...

Read More...

‘Sticking with what we have and selecting superior genetics seen as the way forward’ – Agriland

January 29th, 2021 2:52 am

Sticking with what we have and selecting for superior genetics rather than importing genetics from New Zealand is seen as the way forward for Irish sheep farmers, according to Nicola Featherstone.

Nicola was speaking at the first of two virtual Teagasc Sheep Conferences which were held yesterday evening (Tuesday, January 26).

Teagasc Walsh Scholar Nicola gave an update on the INZAC trial in Teagasc Athenry, Co. Galway, which compares 1-star and 5-star Irish ewes with elite New Zealand ewes.

One question put to Nicola during yesterdays session was how relevant did she think New Zealand sheep are in an Irish context and if they are far superior to what we have here in Ireland?

She explained: During my time in New Zealand, along with visiting a number of farms, I also collaborated with a consultancy company and over there we generated a model and that model looked at all different scenarios that we could put into practice here in Ireland.

For example, whether or not we would look at importing New Zealand genetics or should we stick with what we have here in Ireland or maybe a mixture of both.

From looking at the results, it showed that the benefit, in terms of genetics and economics, would be greater for the Irish industry if we stuck with what we have rather than importing New Zealand genetics, as long as we source our genetics from more progressive breeders.

So, essentially, it means that we need commercial farmers to drive demand towards sourcing animals of superior genetics.

If we stick with the system we have which identifies the elite animals, in terms of being 5-stars, then this is the best way forward for Irish sheep farmers.

RELATED STORIES

See the original post here:
'Sticking with what we have and selecting superior genetics seen as the way forward' - Agriland

Read More...

WSU’s first class of medical students will graduate this spring – The Daily Evergreen

January 29th, 2021 2:50 am

Thousands of Firsts campaign celebrates students, faculties early memories of program

COURTESY OF ELSON S. FLOYD COLLEGE OF MEDICINE

Weve been conceiving this idea for nearly four years now, to capture all of these firsts, all of these amazing moments that have occurred since the start of the medical school, said Christina VerHeul, director of communications, marketing and strategic operations at WSUs College of Medicine.

WSUs Elson S. Floyd College of Medicine will graduate its first class of medical students at the end of the spring 2021 semester.

In 2017, the colleges dean welcomed the first class of students, said Christina VerHeul, director of communications, marketing and strategic operations at WSUs College of Medicine. The dean shared a quote during the event: The beauty of the first time is that it leads to 1,000 firsts.

VerHeul said this inspired a campaign to capture all the thousands of firsts that will happen for the students and the school. The college has been collecting students and faculties first memories since then.

It is the largest and most expensive ad campaign the college has done. This milestone is a significant moment for the college and it needs to be celebrated, she said.

Weve been conceiving this idea for nearly four years now, to capture all of these firsts, all of these amazing moments that have occurred since the start of the medical school, VerHeul said.

This is not just about the medical school, she said. They want to share the success of the students with every Washingtonian. Everyone from the taxpayers and patients to health care professionals were involved in making this medical school a reality.

We really wanted to bring the state together, especially in this really difficult time, particularly in the health care community, VerHeul said. Theres a little bit of light out there this year that we feel is such an exciting thing.

Senior medical student Christie Kirkpatricks story is incorporated into the campaign. Her story is just one of the many firsts from the students, VerHeul said.

Christie had this incredible first where she delivered her first baby alongside the doctor who delivered her, she said.

Kirkpatrick said she realized in college that medical school was a good fit for her. It felt like a natural starting point because she had grown up in a family of medical doctors.

Working as my fathers medical scribe made me realize I wanted to pursue medicine, she said.

Kirkpatricks favorite memories include seeing her father care for patients and clue into what they really need. She said she would like to practice primary care and specialize in internal medicine.

Part of the reason I am choosing my specialty is because we get to do everything, she said. If I had to pick my favorite, I like preventative medicine and lifestyle changes, so thinking about metabolic disease.

Kirkpatrick said the COVID-19 pandemic is emotionally challenging for her, but she thinks it will make her a better doctor in the long run.

She acquired a greater appreciation for life and became more resilient. Kirkpatrick said this pandemic really showed her where the problems are within the medical system.

She said she hopes to be a pillar for her patients and to be compassionate and comforting. She is encouraging everyone to not lose hope, to keep their heads up and to know they are loved.

The campaign for the medical school can be viewed on the WSU Elson S. Floyd College of Medicine website and YouTube channel.

See the original post here:
WSU's first class of medical students will graduate this spring - The Daily Evergreen

Read More...

Husband-and-Wife Medical Duo Confront the Deficiencies of America’s Healthcare System in New Documentary – PRNewswire

January 29th, 2021 2:50 am

LOS ANGELES, Jan. 27, 2021 /PRNewswire/ -- Medicine thought leaders,entrepreneurs and board-certified osteopathicpractitioners, Dr. Vincent Apicella and Dr. Mariaclara Bago, known asDr. A & B,areredefining the currenthealthcare system by combining the best of traditional and alternative medical strategies.

Utilizingtheir comprehensive knowledge and passion for health and wellness, the husband-and-wife duo arestarring in the documentary,The Blob Blob Fish: A Journey Through Obesity,set to be released this summer.Produced and directed by Andrew Mossop (DreamsWorks, MTV, VH1), the filmis an upliftingand thought-provokingdocumentary which highlights the flaws in our current healthcare model.

The Blob Blob Fish: A Journey Through Obesitybeautifully demonstrates Dr. A & B's methodsbyexamining the benefits of drastic lifestyle changes on weight loss. In it, three patients, including a teenage boy who is deemed the "blob blob fish" by his peers, embark on a transformative, inspiring, and heartwarming journey to improve their health, self-esteem and overallquality of life.

"I wish everyone understood that they don't need to depend upon insurance, drugs, or the government for better health," says Dr. A. "We want to show the differences people can make in their own healthcare by starting with a moreholistic approach, andthentraditional medicine second. "Or on an as-needed basis," adds Dr. B.

The mission of the film is to redefine how health is perceived in this country. With a culture stuck on the path of least resistance, thismentality has led to trillions of dollars of healthcare spending and very minimal impact on chronic diseases.

Dr. A & B practice functional medicine,a root-cause, holistic, and natural approach that addresses the body as a whole when treating specific medical problems. Their preventative method can often target and cure healthailmentsbeforetraditional medicine techniques like drugs andsurgery arerequired.

Tointerview Dr. A & B, contact EKC PR at 310-441-1000 or email -[emailprotected].

About Dr. A & B

Dr. A & B have been applying their "life changing through lifestyle altering" treatments by way of theirintegrative medicalpractice for the last 15 years, including running their own renowned health and wellness center in Wellington, FL.

SOURCE Dr. A & B

https://draandb.com

Read the rest here:
Husband-and-Wife Medical Duo Confront the Deficiencies of America's Healthcare System in New Documentary - PRNewswire

Read More...

Ask an expert: Finlay Maguire on using genomic data to better understand how COVID19 and its variants behave – Dal News

January 29th, 2021 2:50 am

Its not uncommon for viruses to transform during their life cycle and while understanding the process and rate at which they evolve is incredibly complex, its extremely important for developing preventative medicines and treatments that will mitigate against transmission and any serious health impacts experienced by infected individuals.

In recent months, confirmation of several more prominent variants of the SARS-CoV-2 virus (the cause of the ongoing global pandemic), have been made in the United Kingdom, South Africa and Brazil with two of those variants recently detected in Nova Scotia. As these new variants are believed to spread more quickly, its critical that scientists continue to study and document these mutations so that public health officials can control their spread and ensure that current COVID-19 tests are able to detect all variants of the virus and vaccines able to defend against them.

One of the ways in which scientists are able to detect and track variants of the COVID-19 virus and also other viruses, is through technology known as genome sequencing. We asked Finlay Maguire, who specializes in the fields of public health, epidemiology and bioinformatics and is the Faculty of Computer Science's Donald Hill Family Fellow, to explain how genomic data can be used to help fight against COVID-19.

What exactly is genome sequencing?

Genome sequencing is any of several methods that we use to work out the make-up of all the genetic material in an organism or virus. These methods and the analysis of the data that they produce are foundational to modern life sciences/medicine. Genome sequencing is being actively used to help understand the evolution and epidemiology of the SARS-CoV-2 virus i.e., how the virus is changing and spreading over time. Led by Jalees Nasir in Prof. Andrew McArthurs lab at McMaster University, we, along with many other groups, have done research comparing the strengths and weaknesses of different methods to sequence the genome of SARS-CoV-2. The raw data generated by genome sequencing requires a fair amount of computational processing to remove errors and identify any variants.

In an interesting bit of cross-discipline collaboration, I worked with a cosmologist from the Perimeter Institute (Prof. Kendrick Smith) to scale up the methods being used to do this in the McArthur lab. This has enabled hundreds to thousands of genomes to be processed at the same time and is now used by McMaster and the Public Health Agency of Canada for this particular type of sequencing.

How can genomic data be used to predict the evolution of SARS-CoV-2? How does this information help scientists develop vaccines that fight against current and future genetic variants of the virus?

Genomic data gives us the precise genetic fingerprint of the virus that infected the person or animal from which it was sampled. By comparing this fingerprint to the genomes of other SARS-CoV-2 viruses, we can investigate how the virus is spreading. For example, whether an outbreak is all from one source and what that source is likely to be, such as travel from a specific country or region. The pattern of variations, or differences in genetic material, across these genomes can also be used to predict things like how much SARS-CoV-2 is circulating in a population and how quickly it is being transmitted. Using genomic data to answer epidemiological questions like these is known as Genomic Epidemiology.

In terms of vaccine development, genomic data allows researchers to better understand how the virus infects human cells, how quickly specific components change over time, and thus which parts of the virus to target with a vaccine. Every single SARS-CoV-2 vaccine and vaccine candidate was developed using genomic data in some way. This link is particularly clear in the mRNA vaccines being deployed against SARS-CoV-2, as these vaccines are based on a copied portion of the viral genome. We also use genomic sequencing to monitor whether a virus has evolved to overcome the vaccine. By sequencing any person that might become infected after being vaccinated, we can determine how the virus has changed and whether the vaccine needs updating.

Given recent news that mutations of the COVID-19 virus have been found in areas like Great Britain and Canada, are researchers around the world collaborating in the study of these mutations? If so, how are they tracking sharing this information?The analysis of SARS-CoV-2 is a truly international and cross-discipline effort, with open and rapid sharing of data, tools, and preliminary findings outside of traditional (and slow) academic publishing channels. There are currently over 425,000 genomes deposited in databases such as the European Nucleotide Archive and GISAIDs EpiCoV through the work of individual research groups and national sequencing initiatives such as the Canadian COVID-19 Genomics Network (CanCOGeN).

However, genomes are only so useful without accompanying high-quality metadata (e.g., details about the genomes such as when/where the genome was collected). To this end, as part of the Public Health Alliance for Genomic Epidemiology, we (led by Dr. Emma Griffths at the BCCDC/Simon Fraser University) have developed international consensus standards to try and ensure that everyone is generating consistent, specific, usable metadata with their sequencing. This allows us to more easily collaborate on a global scale to study this virus.

To enable all this data to be used effectively, open-source projects such as Nextstrain develop tools and facilitate the sharing of results. These projects allow researchers and public health officials to analyse data from their area of interest and automatically sample the global data to provide context for their results. Through a collaboration with Ontarios ONCoV Genomics Rapid Response Coalition and Prof. Andrew McArthur, I currently maintain and host a continually updated evolutionary analysis of SARS-CoV-2 in Canada using these tools.

How have insights gained from genome sequencing been used by governments and health officials to develop policy and protocols to manage the global pandemic and spread of the virus?

Historically, the process of sequencing and analyzing genomic data took too long to actively drive public health policy/interventions during an active outbreak. Thanks to work on improving open international standards and infrastructure through initiatives like the Public Health Alliance for Genomic Epidemiology, Nextstrain, and Canadas Integrated Rapid Infectious Disease Analysis project, it is now possible to perform genomic epidemiological analyses in essentially real-time.

This has allowed the genomic epidemiology of SARS-CoV-2 to inform public health interventions throughout the pandemic at every level from the imposition of international travel restrictions to try to control the spread of new rapidly transmitting variants down to changes in cleaning and staff-screening policies within single hospitals or long-term care facilities to control outbreaks. Beyond this pandemic, genomic epidemiology is likely going to continue to become an increasingly important tool in the management of infectious diseases.

Read the rest here:
Ask an expert: Finlay Maguire on using genomic data to better understand how COVID19 and its variants behave - Dal News

Read More...

Which COVID-19 treatments are working at Louisville-area hospitals? – WLKY Louisville

January 29th, 2021 2:50 am

BATTLE AGAINST THE DEADLY VIRUS. REPORTER: EVEN WITH THE VACCINATION ROLLOUT, THE FIGHT AGAINST COVID-19 IS FAR FROM OVER. IT IS WHY EVERY PATIENT WHO LEAVES THE HOSPITAL OR NEVER EVEN HAS TO BE ADMITTED IS CELEBRATED AS A VICTORY. [APPLAUSE] >> W ARE PREVENTING PEOPLE FROM GETTING PROFOUNDLY ILL. IF YOU CAN D THAT AND THEY CAN GET BACK TO THEIR LIVES THAT IS WHAT MEDICINE IS ABOUT AT THE END OF THE DAY. REPORTER: DR. JOE FLYNN WITH NORTON HEALTHCARE IS PART OF A TEAM OF RESEARCHERS THATS BEEN WORKING WITH MONO-COLONAL ANTIBODIES FOR MONTHS. ALREADY THIS WEEK, 30 COVID PATIENTS WERE GIVEN THE DRUG 500 IN RECENT WEEKS, AND OF THOSE, ONLY 3 HAD TO BE HOSPITALIZED. IN ORDER TO KEEP HOSPITALS AND STAFF FROM BECOMING OVERWHELMED DOCTORS SAY IT IS IMPORTANT TO KEEP NUMBERS LOW. NORTON HEALTHCARE REPOR 182 COVID RELATED HOSPITALIZATIONS. AT BAPTIST, 74, AND TO HEALTH SAYS THEY HAVE JUST UNDER 100. U OF L HEALTH, IN PART BECAUSE OF THEIR RENOWNED CARDIAC TEAM, IS FINDING THEMSELVES WELL EQUIPPED TO DEAL WITH THOSE IN THE ICU. ECMO, OXYGENATING A PATIENTS BLOOD TO ALLOW THEIR LUNGS AND HEART TO HEAL, HAS ALREADY SAVED 5 LIVES THIS YEAR, ACCORDING T SURGEON MATTHEW FOX. >> AS SURGEONS WE DO NOT GET TO TREA COVID PATIENTS AS MUCH AS OUR CRITICAL-CARE CARE COLLEAGUES THAT SEE IT EVERY DAY THERE IT BEING ABLE TO CONTRIBUTE IN YOUR OWN WAY. REPORTER: BUT EVEN WITH ADVANCEMENTS BEING MADE DAILY, DOCTORS CAUTION THERES A LONG WAY TO GO. PREVENTATIVE MEASURES LIKE MASKS AND SOCIAL DISTANCING MUST CONTINUE TO BE FOLLO >> WHEN WE STARTED IN MARCH AND APRIL WE WERE STILL TRYING TO INVENT THE WHEEL. WE MIGHT BE DRIVING A MODEL T BUT WE HAVE A LONG WAY TO GO. OUR TICKET OUT OF THIS IS THROUGH THE VACCINE. REPORTER: ANOTHER INCREDIBLE STEP, JUST AS INCREDIBLE AS MEDICINE, DR. FLYNN SAYS, IS THE MANPOWER. >> I LOVE SCIENCE. THAT IS WHAT I DO. THE THING THAT HAS BEEN TRANSFORMATIVE IS THE HUMAN REACTION AND WHAT PEOPLE HAVE STEPPED UP TO DO FOR OTHERS IS JUST SO UPLIFTING TO ME.

Which COVID-19 treatments are working at Louisville-area hospitals?

Updated: 6:58 PM EST Jan 28, 2021

Even with the vaccination rollout, the fight against COVID-19 is far from over. It's why every patient who leaves the hospital, or never even has to be admitted, is celebrated as a victory."We're preventing people from getting profoundly ill and they're quickly going back to their lives. That's what medicine's really all about at the end of the day," Dr. Joe Flynn, with Norton Healthcare, told WLKY.Flynn has been part of a team of researchers that has been working with monoclonal antibodies for months. Already this week, 30 COVID-19 patients were given the drugs. In recent weeks, that number was 500, and of those, only three had to be hospitalized. Flynn said it's critical to keep those numbers lower, so that hospitals and staff don't get overwhelmed.Currently, Norton reports 182 COVID-19-related hospitalizations, there are 98 at UofL Health, while Baptist Health has 74 COVID-19 hospitalizations.UofL Health, in part because of their renowned cardiac team, is finding themselves well equipped to deal with those in the ICU. ECMO, oxygenating a patient's blood to allow their lungs and heart to heal, has already saved five lives this year, according to surgeon Dr. Matthew Fox."As surgeons, we don't get to treat COVID patients as much as our critical care colleagues that see it every day, and being able to contribute in your own way is nice," Fox said.But even with advancements being made daily, doctors caution there's a long way to go. Preventative measures, like masks and social distancing, must continue."When we started in March or April, we were in the Stone Age, trying to invent the wheel now we might be driving a model T, but we've got a long way to go. Our ticket out of this is through the vaccine," Dr. Benjamin Klausing, an infectious disease specialist with Baptist Health, said.The development of multiple vaccinations signals an incredible step in the fight against COVID-19. But just as incredible as the medicine, Dr. Flynn said, is the manpower."I love science, that's what I do, but to me the thing that has been transformative is human reaction and what people have stepped up to do for others it's so uplifting to me, that's what I take from all of this," he said.Kentucky is currently in Phase 1B of the vaccination rollout. Area doctors suspect the greater population will not be vaccinated until late summer or early fall.

Even with the vaccination rollout, the fight against COVID-19 is far from over. It's why every patient who leaves the hospital, or never even has to be admitted, is celebrated as a victory.

"We're preventing people from getting profoundly ill and they're quickly going back to their lives. That's what medicine's really all about at the end of the day," Dr. Joe Flynn, with Norton Healthcare, told WLKY.

Flynn has been part of a team of researchers that has been working with monoclonal antibodies for months. Already this week, 30 COVID-19 patients were given the drugs. In recent weeks, that number was 500, and of those, only three had to be hospitalized. Flynn said it's critical to keep those numbers lower, so that hospitals and staff don't get overwhelmed.

Currently, Norton reports 182 COVID-19-related hospitalizations, there are 98 at UofL Health, while Baptist Health has 74 COVID-19 hospitalizations.

UofL Health, in part because of their renowned cardiac team, is finding themselves well equipped to deal with those in the ICU. ECMO, oxygenating a patient's blood to allow their lungs and heart to heal, has already saved five lives this year, according to surgeon Dr. Matthew Fox.

"As surgeons, we don't get to treat COVID patients as much as our critical care colleagues that see it every day, and being able to contribute in your own way is nice," Fox said.

But even with advancements being made daily, doctors caution there's a long way to go. Preventative measures, like masks and social distancing, must continue.

"When we started in March or April, we were in the Stone Age, trying to invent the wheel now we might be driving a model T, but we've got a long way to go. Our ticket out of this is through the vaccine," Dr. Benjamin Klausing, an infectious disease specialist with Baptist Health, said.

The development of multiple vaccinations signals an incredible step in the fight against COVID-19. But just as incredible as the medicine, Dr. Flynn said, is the manpower.

"I love science, that's what I do, but to me the thing that has been transformative is human reaction and what people have stepped up to do for others it's so uplifting to me, that's what I take from all of this," he said.

Kentucky is currently in Phase 1B of the vaccination rollout. Area doctors suspect the greater population will not be vaccinated until late summer or early fall.

Here is the original post:
Which COVID-19 treatments are working at Louisville-area hospitals? - WLKY Louisville

Read More...

Global Preventative Healthcare Technologies and Services Industry (2021 to 2027) Market Trends and Drivers Quest Diagnostics Incorporated,…

January 29th, 2021 2:50 am

A new informative report on theGlobal Preventative Healthcare Technologies and ServicesMarket has recently been published by DBMR and added to its widespread database which will help to make better strategic decisions in the businesses. such as Company Overview, Financial Overview, Product Portfolio, Business Strategies, and Recent Developments. Moreover, it offers summarized data on various business perspectives such as global market shares, drivers, restraints, recent innovative trends, and challenges in front of the global Preventative Healthcare Technologies and Services market. Preventative Healthcare Technologies and Services industry report firstly introduced the Preventative Healthcare Technologies and Services basics: Definitions, Classifications, Applications and Market Overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region Preventative Healthcare Technologies and Services market conditions, including the product Price, Profit, Capacity, Production, Supply, forecast (2021 -2027), demand, market growth rate etc.

Preventative healthcare technologies and services market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to growing at a CAGR of 11.10% in the above-mentioned forecast period. The growing awareness amongst the physicians and patients regarding the benefits of advance technology as well as services will help in boosting the growth of the market.

Download Free Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-preventative-healthcare-technologies-and-services-market&AS

The major players who are leading the market throughout the globe are:

COVID 19 scenario analysis:

Preventative Healthcare Technologies and Services MarketSegmentation:

By Type (Early Detection and Screening Technologies, Chronic Disease Management Technologies, Vaccines, Advanced Technologies to Reduce Errors)

By Application (Hospitals, Clinics, Others)

MAJOR TOC OF THE REPORT:-

Get Complete Latest TOC of This Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-preventative-healthcare-technologies-and-services-market&AS

Competitive Landscape and Preventative Healthcare Technologies and Services Market Share Analysis

Preventative healthcare technologies and services market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to preventative healthcare technologies and services market.

The major players covered in the preventative healthcare technologies and services market report are Myriad Genetics, Inc., Quest Diagnostics Incorporated., Medtronic, Abbott., Merck & Co., Inc., GlaxoSmithKline plc., Omnicell, Inc., McKesson Corporation, Pfizer Inc., Dilon Technologies, Inc., OMRON Healthcare Europe B.V., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Significant Highlights of the Report:

Global Preventative Healthcare Technologies and Services Market Scope and Market Size

Based on type, preventative healthcare technologies and services market is segmented into early detection and screening technologies, chronic disease management technologies, vaccines, and advanced technologies to reduce errors. Early detection and screening technologies have been further segmented into automated screening, personalized medicine, and other advanced screening technologies. Chronic disease management technologies have been further segmented into blood pressure monitors, asthma monitors, cardiovascular monitors, and glucose monitors.

Make An Enquiry and Ask For Customized Report@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-preventative-healthcare-technologies-and-services-market&AS

Preventative Healthcare Technologies and Services Market Country Level Analysis

About Data Bridge Market Research Private Ltd:

Data Bridge Market ResearchPvt Ltdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.

Contact:

Data Bridge Market Research

US:+1 888 387 2818

UK:+44 208 089 1725

Hong Kong:+852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Read more here:
Global Preventative Healthcare Technologies and Services Industry (2021 to 2027) Market Trends and Drivers Quest Diagnostics Incorporated,...

Read More...

VERIFY: No, ivermectin is not an approved treatment for COVID – WZDX

January 29th, 2021 2:50 am

Ivermectin is showing up in web searches and social media posts about COVID treatments. It's not an approved treatment.

ALABAMA, USA The drug ivermectin has been popping up on Google searches and social media as a treatment for COVID.

What's the story behind ivermectin and COVID? We checked it out.

Sources: National Institutes of Health, FDA,

What is ivermectin?

Ivermectin is an antiparasitic drug that is approved by the Food and Drug Administration (FDA) for certain conditions, particularly parasitic worm infections. It's also commonly used to as a heartworm preventative and to treat some parasitic conditions in animals.

Is ivermectin a treatment for COVID-19?

According to all three of our sources, the answer is that there is research being done, but its usefulness and effectiveness have not been proven, and it's not approved for the treatment or prevention of COVID.

Clinical studies have given conflicting results, and there are major limitations on these studies. The NIH says,

The most frequent limitations cited were the small sizes of the studies and the administration of other medications along with ivermectin, making it hard to assess of the true efficacy or safety of ivermectin.

Conclusion:

While there have been a number of small-scale studies on the effectiveness of ivermectin to treat COVID-19 with varying results, it is not approved as a treatment. Research is still underway.

View original post here:
VERIFY: No, ivermectin is not an approved treatment for COVID - WZDX

Read More...

Health experts say Nevada should step up preventative methods after UK variant strain of COVID-19 is found in the state – KLAS – 8 News Now

January 27th, 2021 9:53 am

LAS VEGAS (KLAS) A new variant of the coronavirus has been found in Nevada, and health officials say it is more contagious than the original strain.

The new strain first emerged in the United Kingdom last fall, and it has been popping up in the United States in recent weeks. The U.K. variant, also known as B.1.1.7, has been found in at least 24 states in the U.S., according to the Center for Disease Control and Prevention (CDC).

It has also been found in Nevada, so some local experts say we should step up our prevention efforts.

Public health measures are increasingly more important, said. Dr. Marc J. Kahn, Dean of the UNLV School of Medicine.

This week, officials announced the U.K. strain of the virus was detected in a specimen from a Las Vegas woman.

Its able to potentially infect more people, according to Dr. Kahn.

Dr. Kahn tells 8 News NOW that it is still unclear whether the U.K. strain is more deadly because more research needs to be done on that front. But experts agree, it is around 50 percent more contagious.

Dr. Kahn says it is not a bad idea for mitigation measures for high-risk groups to be increased. He says that includes double masking.

The greater the barrier you have between yourself and others, the less likely this virus is able to be transmitted, Dr. Kahn said.

Dr. Kahn adds it is also important to keep your time inside places like grocery stores limited, and you should avoid areas with inadequate airflow.

With a more contagious variant, we need to be even more careful, Dr. Kahn said.

While research shows the COVID-19 vaccine is effective against new virus strains, Dr. Jonathan Baktari, CEO and Medical Director for e7 Health, says Pfizer and Moderna are both working on booster shots to fight mutated versions of the virus better.

In other words, modulating the mRNA vaccine to take that variant into account, and then potentially being prepared to give people a booster shot if that becomes necessary, Dr. Baktari said.

Dr. Baktari says these additional doses will only be necessary if the variants continue to cause issues that the current vaccines cannot handle.

Potentially, were going to need to come up with vaccines for mutations if we dont get it under control soon, Dr. Baktari said.

The two-dose system for the vaccine is still the current official recommendation. Dr. Kahn says regardless of what research is left to do, the vaccine is the best form of protection against COVID-19.

As soon as your time comes up to get vaccinated, you have got to get vaccinated, Dr. Kahn said.

8 News NOW asked the Southern Nevada Health District (SNHD) if it is officially recommending any extra steps in light of the new strain. SNHD officials sent the following statement:

The Southern Nevada Health District recommends that everyone continue to take steps to prevent the spread of COVID-19. The same measures we have been advising everyone to take social distancing, wearing face coverings, avoiding large gatherings, staying home if youre sick, washing your hands, and disinfecting surfaces are effective against the variant strain found in one Clark County resident.

Go here to read the rest:
Health experts say Nevada should step up preventative methods after UK variant strain of COVID-19 is found in the state - KLAS - 8 News Now

Read More...

Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine -…

January 27th, 2021 9:53 am

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, including a Phase 2 ready norovirus program, announcedtoday health care economic findings published in the American Journal of Preventative Medicine. Computational modeling simulating norovirus infection and transmission in a community setting showed that a potential norovirus vaccine can avert symptomatic cases and result in cost savings. The study found, among other things, that vaccination against the norovirus can reduce the economic burden of the virus and is cost effective even if priced at $500 per course when vaccinating children under 5 and older adults, a much higher value than previously estimated. The manuscript titled, Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting can be accessed here.

This study highlights the fact that norovirus is highly contagious and can lead to missed school and work, with productivity losses that can add up, said Bruce Y. Lee, MD, MBA, senior author of the study, Professor of Health Policy and Management at the City University of New York (CUNY), and executive director of the Public Health Informatics, Computational, and Operations Research (PHICOR). The preschool-age population can be particularly vulnerable due to heavy social mixing leading to greater spread of the virus, and the older adult population can be susceptible to more severe disease and subsequently experience high rates of outpatient visits and hospitalizations.

The PHICOR team developed a computational simulation model of different segments of the US population and the spread of norovirus to better understand the value of vaccinating children <5 and adults 65 years old against norovirus. The model simulated the spread of norovirus, subsequent clinical outcomes (e.g., symptoms, hospitalization, death) and associated costs (e.g., direct medical, productivity loss), as well as vaccination.

Key Findings:

These important findings confirm our view of the significant potential clinical and economic benefit of a norovirus vaccine, saidAndrei Floroiu, chief executive officer ofVaxart. The significantly higher cost levels from this analysis increase meaningfully our view of the value creation potential of our oral tablet norovirus vaccine. We are very excited to advance our norovirus program with the three clinical trials we expect to start in 2021 and look forward to confirming the efficacy and tolerability profile suggested by the very encouraging data from our previous Phase 1 studies.

Norovirus is the leading cause of acute viral gastroenteritis in all age groups in the United States. However, there are no approved vaccines for noroviruses. Each year, on average, norovirus causes 19 to 21 million cases of acute gastroenteritis and leads to 56,000 to 71,000 hospitalizations and 570 to 800 deaths, mostly among young children and older adults.

Vaxart, Inc. supported the PHICORs research team.

About PHICOR

Since 2007, PHICORs team of scientists and medical, public health, and communication experts have been researching and developing systems and computational approaches, methods (e.g., artificial intelligence (AI), machine learning, data science), models, and tools to help a wide range of decision makers address various health and public health issues. PHICOR helps local, state, and federal governments respond toinfectiousdiseasethreats, ranging from the flu to Ebola to Zika to the current COVID-19 pandemic. For example, during the 2009 H1N1 flu pandemic, the PHICOR team was embedded in the U.S. Department of Health and Human Services (HHS) to help with the national response. This included working with the Department of Homeland Security (DHS) and the Centers forDiseaseControl and Prevention (CDC).

AboutVaxart

Vaxartis a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.Vaxartinvestigational vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury.Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxarts first immuno-oncology indication.Vaxarthas filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxarts strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as should, believe, could, potential, will, expected, plan and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to the potential clinical and economic value of a norovirus vaccine in a community setting; Vaxarts ability to develop and commercialize its vaccine candidates and preclinical or clinical results and trial data; Vaxarts expectations with respect to the advantages it believes its oral vaccine platform can offer over injectable alternatives; and Vaxarts expectations with respect to the effectiveness of its products or product candidates.Vaxartmay not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements thatVaxartmakes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials or preclinical studies, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial and preclinical study data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxarts product candidates may not be approved by the FDA or non-U.S.regulatory authorities; that, even if approved by the FDA or non-U.S.regulatory authorities, Vaxarts product candidates may not achieve broad market acceptance; that aVaxartcollaborator may not attain development and commercial milestones; thatVaxartor its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxarts or its partners control, including the recent outbreak of COVID-19; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; thatVaxartmay not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxarts capital resources may be inadequate; Vaxarts ability to obtain sufficient capital to fund its operations on terms acceptable toVaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the Risk Factors sections of Vaxarts Quarterly and Annual Reports filed with theSEC.Vaxartdoes not assume any obligation to update any forward-looking statements, except as required by law.

References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vaxart is not responsible for the contents of third-party websites.

Continued here:
Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine -...

Read More...

Clinical trial to evaluate whether topical medication can prevent common skin cancer – Brown University

January 27th, 2021 9:53 am

PROVIDENCE, R.I. [Brown University] Dr. MartinA.Weinstock, a professor of dermatology and epidemiology at Brown University, will lead a six-year clinical trial to evaluate the effectiveness of a topical medication as a way to prevent the most common type of cancer in the United States.

Backed by a $34 million award from the U.S. Department of Veterans Affairs Cooperative Studies Program, the study will investigate the potential of imiquimod, a topical medication with minimal side effects, as a preventive measure against basal cell carcinoma. Weinstock who is the chief of dermatology research for the V.A. Providence Healthcare System will lead the trial with co-chair Dr. Robert Dellavalle, chief of dermatology for the V.A. Eastern Colorado Health Care System and a University of Colorado School of Medicine professor.

Basal cell carcinoma usually occurs on the face and requires surgery to avoid serious complications. An effective preventive medication could help many patients avoid or at least postpone the risks of surgery, and decrease the need for medical visits and their resulting costs, Weinstock said.

These lesions are typically treated with what I call a cut and wait approach, he said, noting that skin damage and scarring are undesirable side effects. Unfortunately, we dont have anything better right now.

More than 1,600 participants, including U.S. military veterans at high risk for basal cell carcinoma, will be recruited from 17 V.A. medical centers for the trial. They will apply the cream to their faces daily for up to 12 weeks and be followed actively for three years to see if their skin cancer risk is reduced, with an additional year of passive follow-up. In addition to evaluating effectiveness of the treatment, researchers will collect genetic material from some participants to determine factors that may indicate greater risk reduction and better tolerance of imiquimod therapy. This will help target therapy to those who will benefit from it the most.

Weinstock said that developing ways to actively prevent basal and squamous cell carcinoma has been a goal since he joined the Brown faculty in 1988. He has been involved with two other national studies directed at skin cancer therapies one of these clinical trials found that topical application of a cream containing 5-fluorouracil 5% reduced the risk of squamous cell carcinoma by 75% for a year.

Theres good reason to believe that well see in this upcoming trial that imiquimod has similar preventative effects on BCC, Weinstock said. And if that turns out to be the case, he said, it would fundamentally transform our approach to the disease we need to proactively prevent this cancer that afflicts millions each year."

See original here:
Clinical trial to evaluate whether topical medication can prevent common skin cancer - Brown University

Read More...

Health experts strongly suggest keeping up with preventative screenings during COVID-19 pandemic – KHOU.com

January 27th, 2021 9:53 am

We can all agree that a trip to the doctors office is no fun but doctors said putting off primary care is not an option.

HOUSTON The COVID-19 pandemic has pushed health priorities for many people to the forefront of their lives while other things have been placed on the back burner.

However, healthcare experts warn preventative checkups shouldnt be one of them.

We can all agree that a trip to the doctors office is no fun but doctors said putting off primary care is not an option.

We clearly saw during the peak of the pandemic in the summertime, we had people delaying care and having worse outcomes than they should have had because they put off the emergent evaluation of symptoms, Dr. James McDeavitt, dean of clinical affairs at Baylor College of Medicine said.

McDeavitt said ignoring health screenings can put you at risk.

When we look at the death rate for this past year unfortunately I think were going to see a death rate that exceeds COVID-19. Were going to see a higher rate of heart disease deaths and cancer deaths, and deaths from pulmonary disease, deaths from stroke because of care thats already been delayed, McDeavitt said.

In addition, UTHealth associate professor and pediatrician, Dr. Sandy McKay, said its not just adults. McKay said when it comes to children theres been a significant drop in vaccinations across the country.

Seeing as much as a 40% decline since COVID which is huge because these are vaccine-preventable illnesses that now children could be potentially be exposed to, McKay said.

She said regular checkups and care will help kids stay healthy during the pandemic.

We do not need to add something like measles or pertussis outbreak in a school which is going to add that much more layer of complexity to dealing with the pandemic, McKay said.

While most physicians have appointment availability both health experts encourage folks to take advantage of telemedicine if theyre concerned about visiting a doctors office. Their main goal is for you to stay on top of your health.

See the original post here:
Health experts strongly suggest keeping up with preventative screenings during COVID-19 pandemic - KHOU.com

Read More...

Editorial: Vaccines can be the game-winning shot – The Reporter

January 27th, 2021 9:53 am

The state Department of Health announcement Tuesday that all Pennsylvania residents 65 years and older are eligible for the COVID-19 vaccine is good news in this ongoing battle against a pandemic that has claimed more than 400,000 lives in the U.S. in the past 10 months.

But expanding the eligibility doesnt get the preventative medicine in peoples arms. As long as a majority remain unvaccinated, the virus will continue spreading -- at an even faster rate with mutations that are taking hold.

The lags in getting vaccinated are for the most part due to supply and demand. In a state like Pennsylvania where 2.27 million people are over 65, there are just not enough doses. So far Pennsylvania has received only about 900,000 doses, according to the state Department of Health.

While that news is frustrating, there is encouragement that supplies will be replenished as manufacturing ramps up as additions from drugmakers AstraZeneca and Johnson & Johnson are expected to get FDA review and enter the pipeline in coming weeks.

And it is inevitable that states and counties will get better at the distribution and availability of vaccine, as well as boosting the signup capability. Right now, systems are crashing and people are waiting hours just to get access to websites to register for appointments.

However, what is even more troubling as thousands wait for the chance to be vaccinated is the reluctance among those who can get the vaccine and the skepticism being spun by naysayers.

In Berks County, Phil Salamone, public information officer of the Berks County EMS COVID-19 Joint Task Force and director of operations for Lower Alsace Ambulance, estimated there are 300 to 400 total workers in the ambulance crews in Berks and about a third of them "simply aren't interested in obtaining the vaccine."

Some of the reasons for refusing the vaccine might be that younger people don't believe getting COVID will do them much harm, while other people have heard of side effects that are simply rumors and have no basis in science; those who had COVID believe they are immune anyway, and some people simply bristle at what they consider to be a herd mentality.

"The message needs to be that if we're going to get through this pandemic we need to vaccinate as many people as possible. We wouldn't recommend something if the benefit didn't outweigh the risk," Dr. Robert J. Tomsho told The Reading Eagle. Tomsho is medical director of the emergency medicine institute, Lehigh Valley Health Network, and oversees training for ambulance crews.

The Moderna and Pfizer vaccines are essentially 100 percent effective against serious disease, Dr. Paul Offit, the director of the Vaccine Education Center at Childrens Hospital of Philadelphia, told David Leonhardt for The New York Times "The Morning" newsletter. Its ridiculously encouraging.

These vaccines are among the best vaccines ever created, with effectiveness rates of about 95 percent after two doses, Leonhardt wrote. If there is an example of a vaccine in widespread clinical use that has this selective effect prevents disease but not infection I cant think of one! Dr. Paul Sax of Harvard has written in The New England Journal of Medicine, dismissing speculation that getting a vaccine won't stop the spread.

"The risks for vaccinated people are still not zero, because almost nothing in the real world is zero risk. A tiny percentage of people may have allergic reactions. But the evidence so far suggests that the vaccines are akin to a cure," Leonhardt wrote.

Concerns are reported to be even more widespread among low-income and people of color, even though those populations have suffered the most cases and deaths. Officials in Montgomery County addressed those concerns head-on Thursday night in a town hall with Black church leaders encouraging their communitiues to participate and air their concerns.

The lack of supply, lack of an orderly and well-communicated system of distribution, and misinformation about vaccine safety have all contributed to diminishing the initial excitement that followed the approval of vaccines. The value, however, is as important as ever.

A few decades ago, the nation underwent a rollout of another vaccine that successfully eradicated polio, and then more vaccines for measles, mumps and rubella all of them having dramatic effect on public health and saving thousands of lives. This rollout needs to proceed with the hopeful enthusiasm that accompanied those vaccines. Efficiency and communication should be easier, not harder, in this age of technology and internet sophistication.

This vaccine remains our best chance to tame the pandemic and restore normalcy. This is our best shot; we need to take it.

See more here:
Editorial: Vaccines can be the game-winning shot - The Reporter

Read More...

Roseville native named Family Physician of the Year – C&G Newspapers

January 27th, 2021 9:53 am

Dr. Kathy Rollinger recently was named the 2020 Family Physician of the Year by the Michigan Association of Osteopathic Physicians.

Photo provided by Kathy Rollinger

Advertisement

ROSEVILLE Dr. Kathy Rollinger has been practicing medicine in southeast Michigan for her entire career and has saved and changed untold lives during that time.

Recently, her service was honored by the Michigan Association of Osteopathic Physicians, which named her the 2020 Family Physician of the Year.

Its very humbling to be recognized by the peers within your organization and for promoting family medicine in the area where you grew up and were raised, she remarked.

A Roseville native, Rollinger has spent her career helping residents on the east side.

I was raised in Roseville and went through Roseville schools and lived there for more than 30 years. My practice is in St. Clair Shores, and I live in Clinton Township. Basically, after medical school, you have to do a residency in what area youre interested in, and I became affiliated with both St. Johns (Hospital) and Beaumont (of Grosse Pointe) and went into family medicine. This is everything from delivering babies to individuals who are in their later years.

Rollinger said she loves working in family medicine and wishes more doctors would go into it since it offers more complete help to patients and requires a fuller knowledge of medicine on the part of the physician.

Family medicine is a specialty with a whole person approach to medicine, she explained. As an osteopathic family physician, our philosophy is to regard your body as an integrated whole. During medical school, we receive additional training in the musculoskeletal system. After completing medical school, and receiving your DO or MD degree, an additional three years of supervised training is required in family medicine. This training covers general medicine and specialty areas including preventative health care. I have been fortunate to incorporate low risk obstetrics, delivering babies and pediatrics into my family medicine practice.

She had to be nominated by her colleagues for the award.

You are nominated by fellow colleagues within the profession, and then a committee would vote on it, said Rollinger. I won a different award last year from them, the Distinguished Service Award. A few of my colleagues within the Michigan Association of Osteopathic Physicians were familiar with my work, and I think one of them nominated me.

Unbeknownst to Rollinger at the time, it was a former Michigan State University classmate of hers who nominated her for the award: Dr. Steve Swetech.

I have watched my classmate evolve into an exemplary osteopathic family physician, Swetech wrote in his nomination letter. She is the prime example of a hard-working successful female physician who even delivers babies! She is a pillar of her community and a champion for women in the medical profession.

Rollinger said being a doctor can be a double-edged sword, providing untold challenges but also being the most fulfilling thing she could imagine.

I think one of the most challenging aspects of family medicine is trying to provide comprehensive care in a real efficient manner, she said. I also work with family medicine residents, so I am helping teach them, and that is challenging, but the hardest parts are the time constraints because you want to give people the best care but only have so much time. I enjoy taking care of individuals and families the best. Getting to take care of babies I deliver and then continuing to take care of that family as they grow up is incredibly rewarding.

Rollinger also received the Michigan Osteopathic Associations Women of Excellence Award for 2020, which she said was nearly as much of an honor.

I think female physicians have continued to excel in the profession, and I am appreciative to work for a major hospital, Beaumont, and feel very supported by them, she said.

Rollinger added that being a family doctor allows her to be often both the first and last line of defense as people fight for their health.

There could be more awareness in the full spectrum in what family practitioners can provide to families, she said. I feel well trained in pediatrics, geriatrics and general medicine and so forth, and I certainly value my consultants in the specialty areas, but I think there is a special value of having a family doctor who knows everything about you and sees the whole picture.

Swetech said he could think of no other colleague more deserving for recognition than Rollinger.

She is a credit to her family, her schools and to society as a whole, wrote Swetech in his nomination letter. I entreat you to give serious consideration to the warrior and champion of womens recognition in the medical profession. Susan B. Anthony would be proud of this trailblazing osteopathic family physician.

Advertisement

Read the original:
Roseville native named Family Physician of the Year - C&G Newspapers

Read More...

Page 222«..1020..221222223224..230240..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick